Skin Grafts for Injuries with CC/MCC DRG Reimbursement

DRG 904 encompasses inpatient cases involving skin grafting for injury with a Complication or Comorbidity or a Major Complication or Comorbidity; it captures increased clinical complexity from comorbid conditions and postoperative complications. This grouping matters for inpatient reimbursement because the assigned Diagnosis-Related Group affects relative weights and payment levels under Medicare for resource use associated with grafting and concurrent conditions.

DRG 904 Overview

DRG 904 covers inpatient admissions for patients who receive skin grafts for traumatic injuries and have at least one Complication or Comorbidity or one Major Complication or Comorbidity. This Diagnosis-Related Group groups cases by the clinical resources associated with operative grafting for wounds and burns when additional comorbid conditions increase complexity. It matters for Medicare payment because the presence of Complication or Comorbidity or Major Complication or Comorbidity influences relative weight and reimbursement. Accurate coding of procedures and secondary diagnoses determines appropriate inpatient payment under Medicare.

Acute operative technique and graft integration studies: randomized or prospective cohort studies comparing different surgical approaches (eg, meshed versus sheet grafts, split-thickness versus full-thickness in select wounds) and adjuncts to optimize graft take in patients with traumatic skin loss or complex degloving injuries. These trials enroll hospitalized adult and pediatric trauma patients requiring operative skin grafting during the index admission, and measure early endpoints such as percent graft take at 7–14 days, need for reoperation, wound infection, and length of stay. Findings inform surgeons and hospital administrators about procedures that reduce reoperations and complications—key drivers of inpatient resource use and DRG cost variance.
Comparative effectiveness research on wound-bed optimization and perioperative care bundles: observational cohorts or pragmatic trials testing strategies such as negative-pressure wound therapy versus standard dressing, timing of grafting after initial debridement, and standardized perioperative antibiotic or glycemic-control bundles in patients with contaminated or high-risk wounds (eg, diabetes, vascular disease, or extensive tissue loss). These studies focus on moderateto-high risk inpatients to determine which pre-graft and perioperative protocols lower infection rates, shorten time to definitive closure, and reduce ICU transfers or prolonged hospitalization. Payers and hospital quality teams use this evidence to adopt care pathways that decrease complications and readmissions tied to higher DRG resource consumption.
Longitudinal outcomes and rehabilitation trials addressing functional recovery and post-discharge utilization: prospective follow-up studies and randomized or controlled rehabilitation interventions that evaluate scar contracture, range of motion, pain, return-to-function, staged reconstruction needs, and health-care utilization in the months to years after inpatient grafting for injury. These trials enroll survivors of major skin loss who were discharged after grafting and assess outcomes such as need for revision surgeries, durable outpatient wound-care costs, prosthetic or orthotic needs, and health-related quality of life. Results are relevant to payers and discharge planners because they identify interventions that reduce downstream costs, prevent costly readmissions or revisions, and improve long-term independence and return to work.

Acute operative technique and graft integration studies: randomized or prospective cohort studies comparing different surgical approaches (eg, meshed versus sheet grafts, split-thickness versus full-thickness in select wounds) and adjuncts to optimize graft take in patients with traumatic skin loss or complex degloving injuries. These trials enroll hospitalized adult and pediatric trauma patients requiring operative skin grafting during the index admission, and measure early endpoints such as percent graft take at 7–14 days, need for reoperation, wound infection, and length of stay. Findings inform surgeons and hospital administrators about procedures that reduce reoperations and complications—key drivers of inpatient resource use and DRG cost variance.
Comparative effectiveness research on wound-bed optimization and perioperative care bundles: observational cohorts or pragmatic trials testing strategies such as negative-pressure wound therapy versus standard dressing, timing of grafting after initial debridement, and standardized perioperative antibiotic or glycemic-control bundles in patients with contaminated or high-risk wounds (eg, diabetes, vascular disease, or extensive tissue loss). These studies focus on moderateto-high risk inpatients to determine which pre-graft and perioperative protocols lower infection rates, shorten time to definitive closure, and reduce ICU transfers or prolonged hospitalization. Payers and hospital quality teams use this evidence to adopt care pathways that decrease complications and readmissions tied to higher DRG resource consumption.
Longitudinal outcomes and rehabilitation trials addressing functional recovery and post-discharge utilization: prospective follow-up studies and randomized or controlled rehabilitation interventions that evaluate scar contracture, range of motion, pain, return-to-function, staged reconstruction needs, and health-care utilization in the months to years after inpatient grafting for injury. These trials enroll survivors of major skin loss who were discharged after grafting and assess outcomes such as need for revision surgeries, durable outpatient wound-care costs, prosthetic or orthotic needs, and health-related quality of life. Results are relevant to payers and discharge planners because they identify interventions that reduce downstream costs, prevent costly readmissions or revisions, and improve long-term independence and return to work.

OpenPayer

Summary & Overview

Skin Grafts for Injuries with CC/MCC: Inpatient Reimbursement Overview

DRG 904 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes